The LongitudinAl Nationwide stuDy on Management And Real‐world outComes of diabetes in India over 3 years (LANDMARC trial)

INTRODUCTION LANDMARC (CTRI/2017/05/008452), a prospective, observational real-world study, evaluated the occurrence of diabetes complications, glycemic control and treatment patterns in people with type 2 diabetes mellitus (T2DM) from pan-India regions over a period of 3 years. METHODS Participants with T2DM (≥25 to ≤60 years old at diagnosis, diabetes duration ≥2 years at the time of enrollment, with/without glycemic control and on ≥2 antidiabetic therapies) were included. The proportion of participants with macrovascular and microvascular complications, glycemic control and time to treatment adaptation over 36 months were assessed. RESULTS Of the 6234 participants enrolled, 5273 completed 3 years follow-up. At the end of 3-years, 205 (3.3%) and 1121 (18.0%) participants reported macrovascular and microvascular complications, respectively. Nonfatal myocardial infarction (40.0%) and neuropathy (82.0%) were the most common complications. At baseline and 3-years, 25.1% (1119/4466) and 36.6% (1356/3700) of participants had HbA1c <7%, respectively. At 3-years, population with macrovascular and microvascular complications had higher proportion of participants with uncontrolled glycemia (78.2% [79/101] and 70.3% [463/659], respectively) than those without complications (61.6% [1839/2985]). Over 3-years, majority (67.7%-73.9%) of the participants were taking only OADs (biguanides [92.2%], sulfonylureas [77.2%] and DPP-IV inhibitors [62.4%]). Addition of insulin was preferred in participants who were only on OADs at baseline, and insulin use gradually increased from 25.5% to 36.7% at the end of 3 years. CONCLUSION These 3-year trends highlight the burden of uncontrolled glycemia and cumulative diabetes-related complications, emphasizing the importance of optimizing diabetes management in India.

[1]  A. Mithal,et al.  1168-P: Complications in the Second Year of LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India , 2022, Diabetes.

[2]  A. Mithal,et al.  1248-P: Glycemic Trend in Metropolitan vs. Nonmetropolitan Cities of India-Two-Year Results of LANDMARC , 2022, Diabetes.

[3]  A. Mithal,et al.  1160-P: Diabetes Complications in Metropolitan vs. Nonmetropolitan Cities of India—Two-Year Results of LANDMARC , 2022, Diabetes.

[4]  A. Mithal,et al.  1219-P: Therapy Trend in the Second Year of LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India , 2022, Diabetes.

[5]  E. Huang,et al.  6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[6]  A. Mithal,et al.  One‐year trends from the LANDMARC trial: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcomes of type 2 diabetes mellitus , 2021, Endocrinology, diabetes & metabolism.

[7]  T. Wong,et al.  Retinal microvascular signs and risk of diabetic kidney disease in asian and white populations , 2021, Scientific Reports.

[8]  A. Mithal,et al.  Baseline characteristics of participants in the LANDMARC trial: A 3‐year, pan‐india, prospective, longitudinal study to assess management and real‐world outcomes of diabetes mellitus , 2021, Endocrinology, diabetes & metabolism.

[9]  V. Mohan,et al.  Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses , 2020, Diabetologia.

[10]  S. Mahadevan,et al.  Prevalence of Vascular Complications Among Type 2 Diabetic Patients in a Rural Health Center in South India , 2020, Journal of Primary Care & Community Health.

[11]  Sujoy Ghosh,et al.  RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020 , 2020, International Journal of Diabetes in Developing Countries.

[12]  A. Mithal,et al.  Rationale, study design and methodology of the LANDMARC trial: a 3‐year, pan‐India, prospective, longitudinal study to assess management and real‐world outcomes of diabetes mellitus , 2019, Diabetic medicine : a journal of the British Diabetic Association.

[13]  Soma Das,et al.  Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study , 2019, BMJ Open Diabetes Research & Care.

[14]  W. Rathmann,et al.  Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program) , 2018, Cardiovascular Diabetology.

[15]  Suresh Kumar,et al.  A study on the glycemic, lipid and blood pressure control among the type 2 diabetes patients of north Kerala, India , 2017, Indian heart journal.

[16]  A. Chawla,et al.  Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? , 2016, Indian journal of endocrinology and metabolism.

[17]  Ranjit Unnikrishnan,et al.  Diabetes mellitus and its complications in India , 2016, Nature Reviews Endocrinology.

[18]  P. Mithra,et al.  Diabetic Peripheral Neuropathy and its Determinants among Patients Attending a Tertiary Health Care Centre in Mangalore, India , 2015, Journal of public health research.

[19]  V. Mohan,et al.  Glycemic control among individuals with self-reported diabetes in India--the ICMR-INDIAB Study. , 2014, Diabetes technology & therapeutics.

[20]  V. Mohan,et al.  Prevalence of peripheral vascular disease and its association with carotid intima-media thickness and arterial stiffness in type 2 diabetes: The Chennai Urban Rural Epidemiology Study (CURES 111) , 2014, Diabetes & vascular disease research.

[21]  P. Wiffen ENHANCED GLUCOSE CONTROL FOR PREVENTING AND TREATING DIABETIC NEUROPATHY , 2012 .

[22]  R. Raman,et al.  Prevalence and risk factors for severity of diabetic neuropathy in type 2 diabetes mellitus. , 2010, Indian journal of medical sciences.

[23]  V. Mohan,et al.  Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES‐55) , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[24]  S. Kalra,et al.  Drug Prescription Patterns and Cost Analysis of Diabetes Therapy in India: Audit of an Endocrine Practice , 2019, Indian journal of endocrinology and metabolism.